4.2 Article

Deubiquitinase Inhibitor Auranofin Attenuated Cardiac Hypertrophy by Blocking NF-κB Activation

Journal

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
Volume 45, Issue 6, Pages 2421-2430

Publisher

KARGER
DOI: 10.1159/000488230

Keywords

Auranofin; Cardiac hypertrophy; Deubiquitinase; Proteasome; NF-kappa B

Funding

  1. National Natural Science Foundation of China [81570259, 81400231, 81774100]
  2. Natural Science Foundation of Guangdong Province [2017A030313796]
  3. Science and Technology Planning Project of Guangdong Province [2014A020212330, 2016A020215167]
  4. Education Features Innovative Project of Guangdong Province [2016KTSCX118, 2016KQNCX134]
  5. Pearl River SAMP
  6. T Nova Program of Guangzhou [201506010071]
  7. Guangzhou Education Commission [1201610098]
  8. Guangzhou Medical, Health Science, and Technology Project [20162A011018]
  9. Foundation of Guangzhou Medical University for Doctor Scientists [2016C17]

Ask authors/readers for more resources

Background/Aims: Cardiac hypertrophy is a major outcome and compensatory response of the cardiovascular system to hemodynamic and additional stress responses that ultimately lead to heart failure. Auranofin (Aur) has been used for treating rheumatic arthritis for several decades. Aur is a 19S proteasome-associated deubiquitinase inhibitor, and inhibition of the proteasome is speculated to reverse cardiac hypertrophy. However, the role of the deubiquitinases, especially 19S proteasome-associated deubiquitinases, in the regulation of cardiac remodeling remains poorly understood. The present study investigated the role of Aur in cardiac hypertrophy both in vitro and in vivo. Methods: Male Sprague-Dawley rats underwent abdominal aortic constriction to induce left ventricular hypertrophy. The neonatal rat primary myocardial cell hypertrophy model was induced by Ang II. Echocardiography, hematoxylin-eosin staining, Masson's trichrome staining, immunochemistry, western blot analysis, a cell viability assay, and enzyme-linked immunosorbent assay were performed. Results: Aur significantly reduced the abdominal aortic constriction that led to left ventricular hypertrophy, reduced heart cavity expansion, and functional disorder, and thereby reduced fetal gene expression and attenuated cardiac fibrosis. Furthermore, Aur caused marked accumulation of ubiquitinated proteins and I kappa B alpha, as well as inactivation of NF-kappa B. This phenomenon was confirmed in the neonatal rat primary myocardial cell hypertrophy model. Conclusions: The present study indicated that Aur blocks the development of left ventricular hypertrophy induced by abdominal aortic constriction. This phenomenon might be attributed to inhibition of the 19S proteasome-associated deubiquitinase that can lead to aggregation of I kappa B alpha and inactivation of the NF-kappa B pathway. Thus, Aur could be a potential anti-cardiac hypertrophy agent. (C) 2018 The Author(s) Published by S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available